EBV-Positive DLBCL, Nos
8 clinical trials · Condition
◉ Watch EBV-Positive DLBCL, Nos
| Record | Firm | Date |
|---|---|---|
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas (NCT05011058) | Viracta Therapeutics, Inc. | 2021-05-28 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857) | Huiqiang Huang | 2021-03-31 |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL (NCT04705129) | Ruijin Hospital | 2021-01-01 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459) | Huiqiang Huang | 2020-07-23 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470) | Huiqiang Huang | 2020-04-24 |
| Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS (NCT04181489) | The First Affiliated Hospital with Nanjing Medical University | 2019-01-01 |
Track EBV-Positive DLBCL, Nos automatically
Every clearance here is in the API, with alerts when new ones post.